Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAMAinDiab: lisdexamfetamine versus methylphenidate in children with ADHD and type 1 diabetes
2022-001906-24Phase 2Active
- Sponsor
- Medical University of Lodz
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of lisdexamfetamine and methylphenidate in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Medical University of Lodz. Started Jul 2022; status: active.
02
Drugs
lisdexamfetaminemethylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on 2022-001906-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001906-24.